Abiopharma

News list

Rhythm Pharmaceuticals Inc (RYTM)

SEC News
Jan. 09, 2026, 14:06 UTC

(90% Positive) RHYTHM PHARMACEUTICALS, INC. (RYTM) Announces Enrollment Update for million Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text

News bot Jan. 9, 2026, 2:08 p.m.

📋 RHYTHM PHARMACEUTICALS, INC. (RYTM) - Clinical Trial Update

Filing Date: 2026-01-09

Accepted: 2026-01-09 09:06:28

Event Type: Clinical Trial Update

Event Details:

Rhythm Pharmaceuticals Inc (RYTM) Announces Clinical Trial Update Rhythm Pharmaceuticals Inc (RYTM) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: million, diseases
Clinical Stage: Phase 3, Phase 3 trial
Collaboration: IMCIVREE®
Updated Timeline: Q4 2025, Q3 2025

🔬 Clinical Development Pipeline (RHYTHM PHARMACEUTICALS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Bivamelagon	DRUG	Phase PHASE2	Hypothalamic Obesity	ClinicalTrials.gov
Setmelanotide	DRUG	Phase PHASE3	Hypothalamic Obesity	ClinicalTrials.gov
Part D: RM-718	DRUG	Phase PHASE1	Hypothalamic Obesity	ClinicalTrials.gov
Part C: RM-718	DRUG	Phase PHASE1	Hypothalamic Obesity	ClinicalTrials.gov
Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)	DRUG	Phase PHASE1	Hypothalamic Obesity	ClinicalTrials.gov
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)	DRUG	Phase PHASE1	Hypothalamic Obesity	ClinicalTrials.gov
Placebo	DRUG	Phase PHASE3	Hypothalamic Obesity	ClinicalTrials.gov
Collagenase Clostridium Histolyticum (CCH)	BIOLOGICAL	Phase PHASE2	Plantar Fasciitis	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Rhythm Pharmaceuticals Inc
CIK: 0001649904
Ticker Symbol: RYTM
Period End Date: 2026-01-09
Document Type: 8-K